How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

34,768 results for

Hypertension Causes

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Global Vascular Protection Therapy for Adults with Hypertension Without Compelling Indications for Specific Agents

they should be on statin therapy. Mean LDL cholesterol was 3.4 mmol/L at baseline and was lowered by 1.0 mmol/L in the simvastatin arm versus the placebo arm. The primary outcome (all-cause mortality) was reduced significantly with simvastatin therapy (HR 0.87; 95%CI, 0.81 to 0.94, NNT=278 patient-years), as was the composite outcome of the first major vascular event (HR 0.76; 95%CI, 0.72 to 0.81). The benefits of simvastatin were similar in the 41% of trial participants with hypertension as in those (...) %) or recent myocardial infarction (within past 3 months) Indication for, but not currently receiving, a beta-blocker Institutionalized elderly Inconclusive evidence Diabetes mellitus Previous stroke eGFR <20 mL/min/1.73 m 2 Contraindications Patient unwilling or unable to adhere to multiple medications Standing SBP <110 mm Hg Inability to measure SBP accurately Known secondary cause(s) of hypertension References Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia

2018 Hypertension Canada

182. Choice of therapy for Adults With Hypertension Without Compelling Indications for Specific Agents

antihypertensive classes. Thiazides There is strong evidence from meta-analyses of 16 placebo-controlled trials to indicate that thiazide diuretics, particularly at low doses (defined as < 50 mg/day hydrochlorothiazide), reduce stroke, myocardial infarction (MI), heart failure, and cardiovascular and all-cause mortality in patients with hypertension (Relative Risk Reduction [RRR], 25% to 30%) . ALLHAT confirmed the central role of thiazide diuretics in first-line therapy of hypertension without compelling (...) trials in patients with atherosclerotic risk factors showed clear reductions in stroke (RR, 0.70; 95%CI, 0.57 to 0.85), MI (RR, 0.80; 95%CI, 0.72 to 0.89), cardiovascular death (RR, 0.74; 95%CI, 0.64 to 0.85) and all-cause mortality (RR, 0.84; 95%CI, 0.76 to 0.94) with these agents (observed effect sizes were similar in patients with and without hypertension) . Although some subjects with blood pressure levels in the normal range were included, the observed benefits are widely felt to be due to blood

2018 Hypertension Canada

183. Prevention & Treatment of Hypertension - Health Behaviour Management

of developing hyperkalemia including: Patients receiving renin-angiotensin-aldosterone inhibitors Patients receiving other drugs that can cause hyperkalemia (eg, trimethoprim and sulfamethoxazole, amiloride, or triamterene) Patients with chronic kidney disease (glomerular filtration rate < 60 mL/min/1.73 m2) Patients with baseline serum potassium > 4.5 mmol/L H. Stress management 1. In hypertensive patients in whom stress might be a contributor to high BP, stress management should be considered (...) Prevention & Treatment of Hypertension - Health Behaviour Management I. Health Behaviour Management | Hypertension Canada Guidelines Subgroup Members: Simon L. Bacon, PhD; Janusz Kaczorowski, PhD; Luc Trudeau, MD; Swapnil Hiremath, MD MPH; Norman RC. Campbell, MD; Michael Roerecke, PhD; Joanne Arcand, PhD RD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C

2018 Hypertension Canada

184. Diagnosis & Assessment of Hypertension - Lab Tests

ventricular hypertrophy (LVH) or a prior myocardial infarction, both of which portend a higher risk of future cardiovascular events and death . Finally, both the routine and optional investigations aid in the screening for some of the modifiable causes of hypertension. For example recurrent and/or severe hypokalemia may indicate the presence of primary hyperaldosteronism. When compared with oral glucose tolerance testing, a systematic review suggests that A1C and fasting glucose levels demonstrate (...) Diagnosis & Assessment of Hypertension - Lab Tests V. Routine and Optional Laboratory Tests for the Investigation of Patients with Hypertension | Hypertension Canada Guidelines Subgroup Members: Brian Penner, MD; Ellen Burgess, MD; Praveena Sivapalan, MD Central Review Committee: Stella S. Daskalopoulou, MD MSc DIC PhD (Chair); Kaberi Dasgupta, MD MSc; Kelly B. Zarnke, MD MSc; Kara Nerenberg, MD, MSc; Alexander A. Leung, MD MPH; Kevin C. Harris, MD MHSc; Kerry McBrien, MD MPH; Sonia Butalia

2018 Hypertension Canada

185. Diagnosis & Assessment of Hypertension - Diagnosis

all visits) is ≥160 mmHg systolic or ≥100 mm Hg diastolic; At visit 4 or 5, mean non-AOBP measurement (averaged across all visits) is ≥140 mmHg systolic or ≥90 mmHg diastolic. Investigations for secondary causes of hypertension should be initiated in patients with suggestive clinical and/or laboratory features (outlined in , VII and II) (Grade D). If at the last diagnostic visit the patient is not diagnosed as hypertensive and has no evidence of macrovascular target organ damage, the patient’s BP (...) . A marked elevation in blood pressure in the presence of acute symptoms or progressive target organ damage in the brain, eye, heart, or kidney is a hypertensive emergency . An asymptomatic severe blood pressure elevation without evidence of target organ damage and not due to an acutely reversible cause (e.g. pain, urinary retention) constitutes a hypertensive urgency . Historically, a ≥180/110 mm Hg has been used to define severe blood pressure elevation ; however, this threshold is arbitrary should

2018 Hypertension Canada

186. Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. (PubMed)

Diagnosing hypertension in Indigenous Canadians (DREAM-GLOBAL): A randomized controlled trial to compare the effectiveness of short message service messaging for management of hypertension: Main results. Hypertension, the leading cause of cardiovascular morbidity and mortality, affects more than 1 billion people globally. The rise in mobile health in particular the use of mobile phones and short message service (SMS) to support disease management provides an opportunity to improve hypertension (...) awareness, treatment, and control, in remote and vulnerable patient populations. The primary objective of this randomized controlled study was to assess the effect of active (with hypertension specific management SMS) or passive (health behaviors SMS alone) on the difference in blood pressure (BP) reduction between the active and passive SMS groups in hypertensive Canadian First Nations people from six rural and remote communities. Pragmatic features of the study included shifting of BP measures to non

Full Text available with Trip Pro

2019 Journal of clinical hypertension (Greenwich, Conn.)

187. Therapeutic hypothermia for intacranial hypertension following traumatic brain injury

indication or modification of technique Investigational Should be taken out of use Nearly established Technology type Procedure Technology use Therapeutic Patient Indication and Setting Disease description and associated mortality and morbidity Intracranial hypertension is an important cause of secondary brain injury. The severity and duration of IH are associated with functional outcomes after TBI. Monitoring of intracranial pressure using different devices is necessary to prevent IH and maintain (...) cerebral perfusion pressure, the fundamental therapeutic goals after TBI. 2 Traumatic brain injury may be caused by a variety of mechanisms. Aetiology of TBI includes traffic accidents, falls, gunshot wounds, sports, combat events and other violence-related Hypothermia for intracranial hypertension: December 2016 2 incidents. 3, 4 TBI ranges in severity from mild to severe, and in addition to short-term impairment, those who sustain TBI often suffer from persistent symptoms. Symptoms may be lifelong

2018 COAG Health Council - Horizon Scanning Technology Briefs

188. Ocular Hypertension

Ocular Hypertension Ocular hypertension (OHT) submit The College submit You're here: Ocular hypertension (OHT) Ocular hypertension (OHT) The CMGs are guidelines on the diagnosis and management of a range of common and rare, but important, eye conditions that present with varying frequency in primary and first contact care. Share options Aetiology Ocular hypertension (OHT) is generally defined as consistently elevated intraocular pressure (IOP) (greater than 21mmHg [2 standard deviations above (...) years Predisposing factors Increasing age Symptoms Usually asymptomatic Signs An untreated IOP >21mmHg (GAT), in one or both eyes confirmed on a separate occasion Open drainage angles on gonioscopy with normal appearance Absence of signs of glaucomatous optic neuropathy (disc changes, field defects) Absence of secondary cause for IOP elevation Differential diagnosis Primary Open Angle Glaucoma (POAG) Primary Angle Closure (PAC) or Primary Angle Closure Glaucoma (PACG) (i.e. without

2018 College of Optometrists

189. Long-term effects of weight-reducing diets in people with hypertension. (PubMed)

Long-term effects of weight-reducing diets in people with hypertension. All major guidelines for antihypertensive therapy recommend weight loss. Thus dietary interventions that aim to reduce body weight might be a useful intervention to reduce blood pressure and adverse cardiovascular events associated with hypertension.Primary objectivesTo assess the long-term effects of weight-reducing diets in people with hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (...) (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse events). Secondary objectivesTo assess the long-term effects of weight-reducing diets in people with hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction.We obtained studies from computerised searches of the Cochrane Central Register of Controlled Trials (CENTRAL), the Cochrane Hypertension Specialised Register

2016 Cochrane

190. Long-term effects of weight-reducing drugs in people with hypertension. (PubMed)

Long-term effects of weight-reducing drugs in people with hypertension. All major guidelines on antihypertensive therapy recommend weight loss; anti-obesity drugs may be able to help in this respect.To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on all-cause mortality, cardiovascular morbidity, and adverse events (including total serious adverse events, withdrawal due to adverse events, and total non-serious adverse (...) events).To assess the long-term effects of pharmacologically induced reduction in body weight in adults with essential hypertension on change from baseline in systolic blood pressure, change from baseline in diastolic blood pressure, and body weight reduction.We obtained studies using computerised searches of the Cochrane Hypertension Group Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, Ovid EMBASE, the clinical trials registry ClinicalTrials.gov

2016 Cochrane

191. Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. (PubMed)

Antihypertensive pharmacotherapy for prevention of sudden cardiac death in hypertensive individuals. High blood pressure is an important public health problem because of associated risks of stroke and cardiovascular events. Antihypertensive drugs are often used in the belief that lowering blood pressure will prevent cardiac events, including myocardial infarction and sudden death (death of unknown cause within one hour of the onset of acute symptoms or within 24 hours of observation (...) of the patient as alive and symptom free).To assess the effects of antihypertensive pharmacotherapy in preventing sudden death, non-fatal myocardial infarction and fatal myocardial infarction among hypertensive individuals.We searched the Cochrane Hypertension Specialised Register (all years to January 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (2016, Issue 1), Ovid MEDLINE (1946 to January 2016), Ovid EMBASE (1980 to January 2016

Full Text available with Trip Pro

2016 Cochrane

192. Mutant Cullin 3 causes familial hyperkalemic hypertension via dominant effects (PubMed)

Mutant Cullin 3 causes familial hyperkalemic hypertension via dominant effects Mutations in the ubiquitin ligase scaffold protein Cullin 3 (CUL3) cause the disease familial hyperkalemic hypertension (FHHt). In the kidney, mutant CUL3 (CUL3-Δ9) increases abundance of With-No-Lysine [K] Kinase 4 (WNK4), with excessive activation of the downstream Sterile 20 (STE20)/SPS-1-related proline/alanine-rich kinase (SPAK) increasing phosphorylation of the Na+-Cl- cotransporter (NCC). CUL3-Δ9 promotes its (...) own degradation via autoubiquitination, leading to the hypothesis that Cul3 haploinsufficiency causes FHHt. To directly test this, we generated Cul3 heterozygous mice (CUL3-Het), and Cul3 heterozygotes also expressing CUL3-Δ9 (CUL3-Het/Δ9), using an inducible renal epithelial-specific system. Endogenous CUL3 was reduced to 50% in both models, and consistent with autoubiquitination, CUL3-Δ9 protein was undetectable in CUL3-Het/Δ9 kidneys unless primary renal epithelia cells were cultured

Full Text available with Trip Pro

2017 JCI insight

193. Purinergic dysregulation causes hypertensive glaucoma–like optic neuropathy (PubMed)

Purinergic dysregulation causes hypertensive glaucoma–like optic neuropathy Glaucoma is an optic neuropathy characterized by progressive degeneration of retinal ganglion cells (RGCs) and visual loss. Although one of the highest risk factors for glaucoma is elevated intraocular pressure (IOP) and reduction in IOP is the only proven treatment, the mechanism of IOP regulation is poorly understood. We report that the P2Y6 receptor is critical for lowering IOP and that ablation of the P2Y6 gene (...) in mice (P2Y6KO) results in hypertensive glaucoma-like optic neuropathy. Topically applied uridine diphosphate, an endogenous selective agonist for the P2Y6 receptor, decreases IOP. The P2Y6 receptor was expressed in nonpigmented epithelial cells of the ciliary body and controlled aqueous humor dynamics. P2Y6KO mice exhibited sustained elevation of IOP, age-dependent damage to the optic nerve, thinning of ganglion cell plus inner plexiform layers, and a reduction of RGC numbers. These changes

Full Text available with Trip Pro

2017 JCI insight

194. Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease

pressure lowering agents in patients with type 2 diabetes who have CKD and albuminuria? 8 Is there a need for long-term outcome studies of non-dihydropyridine calcium channel blockers in diabetic nephropathy? Introduction Diabetic nephropathy is the leading cause of end-stage renal disease and it is characterised by a triad of persistent albuminuria, hypertension and a decline in glomerular filtration rate (GFR). The presence of diabetic nephropathy increases cardiovascular morbidity and mortality (...) Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Hypertension management and renin-angiotensin-aldosterone system blockade in patients with diabetes, nephropathy and/or chronic kidney disease Indranil Dasgupta DM FRCP , Debasish Banerjee MD FRCP , Tahseen A Chowdhury MD FRCP , Parijat De MD FRCP , Mona Wahba MA FRCP , Stephen Bain MD FRCP , Andrew Frankel MD FRCP , Damian Fogarty MD FRCP , Ana Pokrajac

2017 Association of British Clinical Diabetologists

195. Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension

Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension | Innovation Observatory toggle menu Menu Search View All Filter by Speciality Filter by Year Filter by Category This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development (...) as these outputs are produced as required for our stakeholders. > > > Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension Netarsudil plus latanoprost (Roclatan) for glaucoma or ocular hypertension September 2017 Glaucoma describes a group of disorders characterised by sight loss. Glaucoma is generally associated with high pressure in the liquids inside the eye but it can happen when the pressure level is normal. Individuals with consistently high eye pressure are at risk of developing

2017 NIHR Innovation Observatory

196. CRACKCast E084 – Hypertension

go on the be diagnosed after appropriate w/o by GP or outpatient clinic [2] List 10 possible etiologies for hypertension. Remember that hypertension – is either primary or secondary. We always need to think “why” are they HTNsive: Here are some secondary causes: [3] What is the pathophysiology of target-organ damage? Macrocirculation High SVR (due to peripheral arteriole back up from SNS and RAAS activation) increase LV mass LVH – Diastolic dysfunction Elevated LA end diastolic pressures Acute (...) SVR rise = Flash pulmonary edema Chronic = leads to LVH – leads to ischemia (outgrowing blood supply) and eventual thinning of myocardium Thus end with big floppy bag of systolic dysfunction Microcirculation Critical luminal narrowing – occlusion and ischemia “Silent” ischemic episodes lead to primary cause of chronic end organ damage Lumen thinning – aneurysm and rupture Results in tissue edema, fibrinoid necrosis, and microangiopathic hemolytic anemia Now, Hypertensive emergencies get a little

2017 CandiEM

197. Pharmacological Management of Hypertension

Pharmacological Management of Hypertension Pharmacological Management of Hypertension | National Guideline Clearinghouse success fail JUL Aug 12 2017 2018 2019 02 Oct 2017 - 13 Jul 2018 COLLECTED BY Organization: Formed in 2009, the Archive Team (not to be confused with the archive.org Archive-It Team) is a rogue archivist collective dedicated to saving copies of rapidly dying or deleted websites for the sake of history and digital heritage. The group is 100% composed of volunteers (...) * Remember Me Don't have an account? The AHRQ National Guideline Clearinghouse (NGC, guideline.gov) Web site will not be available after July 16, 2018 because federal funding through AHRQ will no longer be available to support the NGC as of that date. For additional information, read our . Guideline Synthesis Pharmacological Management of Hypertension Guidelines Being Compared: American College of Physicians (ACP) Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus

2017 National Guideline Clearinghouse (partial archive)

198. Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period

known that severe hypertension can cause central nervous system injury. As stated in the Confidential Enquiries report from the United Kingdom, two thirds of the maternal deaths during 2003–2005 resulted from cerebral hemorrhage or infarction (5). The degree of systolic hypertension (as opposed to the level of diastolic hypertension or relative increase or rate of increase of mean arterial pressure from baseline levels) may be the most important predictor of cerebral injury and infarction. In a case (...) Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period - ACOG Menu ▼ Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period Page Navigation ▼ INTERIM UPDATE Number 767 (Replaces Committee Opinion Number 692, September 2017) Committee on Obstetric Practice This Committee Opinion was developed by the American College

2017 American College of Obstetricians and Gynecologists

199. Pharmacologic Treatment of Hypertension in Adults Aged 60 Years or Older to Higher Versus Lower Blood Pressure Targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians

with moderate or severe hypertension (SBP >160 mm Hg) at baseline and, with treatment, achieved SBP targets greater than 140 mm Hg. Differing BP Targets Moderate-quality evidence showed a reduction in all-cause mortality among patients with a baseline SBP of 160 mm Hg or greater who achieved a target SBP of less than 150 mm Hg, although the reductions did not quite reach statistical significance (relative risk [RR], 0.93 [95% CI, 0.85 to 1.00]; absolute risk reduction [ARR], 1.13). High-quality evidence (...) blood pressure targets with the patient. Moderate-quality evidence showed that treating hypertension in older adults with previous TIA or stroke to an SBP target of 130 to 140 mm Hg reduces stroke recurrence (ARR, 3.02) compared with treatment to higher targets, with no statistically significant effect on cardiac events or all-cause mortality. Recommendation 3: ACP and AAFP recommend that clinicians consider initiating or intensifying pharmacologic treatment in some adults aged 60 years or older

Full Text available with Trip Pro

2017 American College of Physicians

200. Home health monitoring devices compared with usual care for patients with hypertension

. Epidemiology Hypertension is the medical term for high BP in the arteries and is a chronic condition 11 . It is one of the main preventable causes of premature morbidity and death in the UK 4 and is a major risk factor for cardiovascular disease 5 . BP is defined as the amount of pressure applied to the walls of arteries when blood travels through them 5 . It is measured in millimetres of mercury, or mmHg, and expressed as SBP over (/) DBP 5 . Although it is essentially inaccurate to specify a threshold (...) and another developed hyperkalaemia (of another cause), which antihypertensive drug therapy may have exacerbated. The remaining patients were admitted to hospital with issues considered to be unrelated to the intervention or BP. Cost effectiveness Three economic evaluations were identified that examined the cost-effectiveness of home BP telemonitoring compared to conventional office BP monitoring for patients with hypertension. Two of the three studies – one Danish and one UK – compared the costs

2016 Evidence Notes from Healthcare Improvement Scotland

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>